Involvement of dopaminergic receptors in action of corticotropin releasing factor (CRF) under in vitro conditions.
ACTH release under the effect of median eminence extract (ME) was studied in both incubation and superfusion experiments. ACTH content of the incubation medium was measured by radioimmunoassay or by the corticosterone production of trypsinisolated adrenocortical cells. Dopamine at low concentration led to a slight increase of basal ACTH secretion, while at higher concentration failed to influence ACTH release. The dopamine agonist CB-154 produced a significant rise of ACTH secretion and augmented the ME extract-induced increase of pituitary ACTH release. Chlorpromazine and haloperidol suppressed basal ACTH secretion and inhibited the ME extract-induced release. The simultaneous administration of CB-154 and haloperidol into the incubation medium prevented the haloperidol-induced inhibition of ACTH release. The observations indicate that dopaminergic receptors play a role in the activation of CRF-induced ACTH secretion under in vitro experimental conditions.
D000302:Adrenal Cortex / Q000378:metabolism; D000324:Adrenocorticotropic Hormone / Q000378:metabolism*; D000818:Animals; D001971:Bromocriptine / Q000494:pharmacology; D002746:Chlorpromazine / Q000494:pharmacology; D003345:Corticosterone / Q000378:metabolism*; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology*; D004347:Drug Interactions; D006220:Haloperidol / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D010179:Pancreas; D010903:Pituitary Gland, Anterior / Q000378:metabolism*; D051381:Rats; D011954:Receptors, Dopamine / Q000502:physiology*; D014020:Tissue Extracts / Q000494:pharmacology
D011954:Receptors, Dopamine; D014020:Tissue Extracts; D001971:Bromocriptine; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D006220:Haloperidol; D002746:Chlorpromazine; D003345:Corticosterone